Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition.
Mavroeidis L, Sheldon H, Briasoulis E, Marselos M, Pappas P, Harris AL. Mavroeidis L, et al. Among authors: briasoulis e. Int J Oncol. 2015 Aug;47(2):455-64. doi: 10.3892/ijo.2015.3059. Epub 2015 Jun 19. Int J Oncol. 2015. PMID: 26095084 Free PMC article.
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilas G, Syrigos KN, Kalofonos H, Samantas E. Briasoulis E, et al. BMC Cancer. 2013 May 29;13:263. doi: 10.1186/1471-2407-13-263. BMC Cancer. 2013. PMID: 23718900 Free PMC article. Clinical Trial.
Revisiting bleomycin from pathophysiology to safe clinical use.
Froudarakis M, Hatzimichael E, Kyriazopoulou L, Lagos K, Pappas P, Tzakos AG, Karavasilis V, Daliani D, Papandreou C, Briasoulis E. Froudarakis M, et al. Among authors: briasoulis e. Crit Rev Oncol Hematol. 2013 Jul;87(1):90-100. doi: 10.1016/j.critrevonc.2012.12.003. Epub 2013 Jan 9. Crit Rev Oncol Hematol. 2013. PMID: 23312772 Review.
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A. Briasoulis E, et al. J Clin Oncol. 2000 Oct 15;18(20):3535-44. doi: 10.1200/JCO.2000.18.20.3535. J Clin Oncol. 2000. PMID: 11032596 Clinical Trial.
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
Christodoulou C, Kostopoulos I, Kalofonos HP, Lianos E, Bobos M, Briasoulis E, Gogas H, Razis E, Skarlos DV, Fountzilas G; Study of the Hellenic Cooperative Oncology Group. Christodoulou C, et al. Among authors: briasoulis e. Oncology. 2009;76(4):275-85. doi: 10.1159/000207504. Epub 2009 Mar 5. Oncology. 2009. PMID: 19262067 Clinical Trial.
155 results